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Abstract
Background—Identification of the Mycobacterium tuberculosis immunoproteome and antigens 
associated with serologic responses in adults has renewed interest in developing a serologic test for 
childhood tuberculosis (TB). We investigated IgG antibody responses against M. tuberculosis 
antigens in children with well-characterized TB.
Methods—We studied archived sera obtained from hospitalized children with suspected 
pulmonary TB, and classified as having confirmed TB (culture- confirmed), unlikely TB (clinical 
improvement without TB treatment), or unconfirmed TB (all others). A multiplexed bead-based 
assay for IgG antibodies against 119 M. tuberculosis antigens was developed, validated and used 
to test sera. The area under the curves (AUCs) of the empiric receiver–operator characteristic 
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curves were generated as measures of predictive ability. A cross-validated generalized linear 
model was used to select the most predictive combinations of antigens.
Results—For the confirmed TB versus unlikely TB comparison, the maximal single antigen 
AUC was 0.63, corresponding to sensitivity 0.60 and specificity 0.60. Older (age: 60+ months old) 
children’s responses were better predictive of TB status than younger (age: 12–59 months old) 
children’s, with a maximal single antigen AUC of −0.76. For the confirmed TB versus unlikely TB 
groups, the most predictive combinations of antigens assigned TB risk probabilities of 0.33 and 
0.33, respectively, when all ages were considered, and 0.57 (interquartile range: 0.48–0.64) and 
0.35 (interquartile range: 0.32–0.40) when only older children were considered.
Conclusion—An antigen-based IgG test is unlikely to meet the performance characteristics 
required of a TB detection test applicable to all age groups.
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Childhood tuberculosis (TB) is estimated to account for approximately 10%–20% of the 
global TB disease burden.1 Most pediatric TB disease occurs in low- or middle-income 
countries where timely diagnosis may be especially challenging because of resource 
constraints, lack of capacity to perform microbiologic investigations and a focus on adult 
disease in TB programs.2 Microbiologic diagnosis remains the gold standard, but its 
widespread application is limited by the difficulties in obtaining good-quality respiratory 
specimens especially from very young children, cost and availability of laboratory facilities 
and expertise.3 Even in settings in which etiologic investigation is possible, up to 70% of 
children treated for pulmonary TB (PTB) are still diagnosed clinically using a combination 
of history, symptoms, tuberculin skin testing and chest radiography4,5 as microbiologic 
testing is often negative because of the paucibacillary nature of childhood TB.6,7 In children, 
detection of serum antibodies therefore represents an attractive diagnostic approach, 
focusing on host responses to Mycobacterium tuberculosis rather than attempting to detect 
bacteria or bacterial products. Furthermore, blood specimens can be obtained relatively 
easily.
Historically, serologic tests for TB have typically used 1 or 2 antigens or crude mixtures of 
components and products of mycobacteria. Recent meta-analyses of performance of 
commercially available and in-house tests for serodiagnosis of TB in adults and children8,9 
concluded that test performance varied widely and that none of the tests performed well 
enough to be used routinely. The World Health Organization has issued a strong 
recommendation against the use of available serologic tests for TB diagnosis and has 
advocated for research aimed at developing improved assays.
The advent of proteomic approaches and the recognition of the heterogeneity of antibody 
responses have spawned interest in the identification of antibody signatures, that is, patterns 
of reactivity to a number of M. tuberculosis antigens, whose abundance and presence 
correlate with disease state.10–13 In previous work, high-density arrays of M. tuberculosis–
recombinant protein antigens were used to identify sets of M. tuberculosis antigens whose 
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seroreactivity could serve as a biomarker panel for TB diagnosis. This whole proteome 
approach combined with sera from adults with known TB status allowed for definition of the 
M. tuberculosis immunoproteome,13 comprised of 484 proteins that were recognized by 
serum from at least 1 adult patient with active TB disease. Furthermore, antibody reactivity 
against a subset of 13 proteins within the immunoproteome was associated with active TB in 
adults. The aim of our study was to identify antibody responses to M. tuberculosis protein 
antigens that are predictive of TB status in children 1–15 years of age. Considering that 
antibody responses vary by age, we also aimed to study the predictive power of these 
responses in the older versus younger children.
MATERIALS AND METHODS
Participants
Sera were obtained from children with suspected PTB hospitalized at Red Cross War 
Memorial Children’s Hospital in Cape Town, South Africa, and enrolled in a prospective 
study to evaluate new methods for diagnosis of PTB in children.6 Suspected PTB was 
defined based on cough or difficulty breathing, plus one or more of the following: household 
contact with an infectious TB source case within the preceding 3 months, loss of weight or 
failure to gain weight in the preceding 3 months, a positive (induration ≥10 mm) tuberculin 
skin test (TST) using purified protein derivative (PPD; 2TU, PPD RT23; Staten Serum 
Institute, Denmark, Copenhagen) and a chest radiograph suggestive of PTB. Children were 
excluded if they had received more than 72 hours of TB treatment or prophylaxis. All 
children had received Bacillus Calmette Guerin (BCG) vaccination at birth as provided in 
the National Immunisation Program. A history and physical examination were performed. 
Routine clinical investigations included chest radiography and TST, plus HIV testing in 
children whose HIV status was unknown. Two consecutive induced sputum specimens were 
obtained and submitted to the study laboratory for smear microscopy, Xpert MTB/RIF 
(Cepheid, Sunnyvale, CA) testing, and liquid culture. Standard TB therapy was initiated at 
the discretion of the treating doctor based on clinical, radiologic and microbiologic 
information.
Definition of TB Status
For study purposes, each child was classified using clinical and microbiologic criteria, 
according to the following definitions: “confirmed TB” (any culture or nucleic acid 
amplification test positive for M. tuberculosis); “unlikely TB,” that is, non-TB respiratory 
disease (culture-negative for M. tuberculosis, no TB treatment given and documented 
resolution or improvement of symptoms and signs at month 3 follow-up visit) or 
“unconfirmed TB” (all other children), consistent with the revised National Institutes of 
Health consensus definitions for diagnostic research.14 The unlikely TB group was further 
divided according to positive or negative TST result.
Blood Sample Collection, Processing and Storage
Blood specimens were collected at enrollment through venipuncture into a serum separator 
tube. Serum was separated (centrifuged at 1000g for 10 minutes at room temperature) within 
2 hours of collection and immediately frozen in aliquots at −80°C.
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Selection of Serum Specimens
Serum specimens were eligible for inclusion in this study if the child was 12–15 years old 
and HIV-negative at the time of serum collection, informed consent for use of stored samples 
had been provided, and there were complete data on microbiologic and clinical features. A 
sample size of 200 children was projected to provide adequate power to discriminate 
between TB groups. Consecutive sera were selected such that 40 (20%) were from children 
classified as confirmed TB, 80 (40%) were from children classified as unconfirmed TB, and 
80 (40%) were from children classified as unlikely TB (39 TST-positive and 41 TST-
negative). Specimens were transported on dry ice to the Natural and Medical Sciences 
Institute at the University of Tuebingen, Reutlingen, Germany, for serologic testing.
Ethics Approvals
Written informed consent for enrollment in the prospective study, including for use of stored 
samples, had been obtained from a parent or legal guardian, and assent had been obtained in 
children older than 7 years of age. Ethics committees of the Faculty of Health Sciences, 
University of Cape Town and Johns Hopkins University approved the study.
Antigen Selection
Antigens were selected from the whole proteome screen on the basis of receiver–operator 
characteristic curves from adult studies, random forest analysis and availability.13,15 We also 
studied additional antigens identified by collaborators as being of interest based on on-going 
vaccine work and/or their inclusion in other studies of antibody reactivity.16 There were 74 
unique antigens, among which 21 were available from different producers, tested in the same 
multiplex. Thus, in total, the assay contained 119 antigens (including recombinant proteins 
and antigen cocktails, subsequently called “antigens”) (Table S1, Supplemental Digital 
Content 1, http://links.lww.com/INF/C768). The multiplex, bead-based Luminex assay was 
used to measure IgG antibodies. This assay was developed, validated and performed on 
study specimens as described in Ref.17 and the online data supplement (Supplemental 
Digital Content 1, http://links.lww.com/INF/C768). For each study sample, a single 
measurement in 1 dilution was performed.
Data Analysis and Sample Size
The aim of this analysis was to identify sets of antibody responses that were predictive of 
TB status. The area under the curve (AUC) and the best antibody response cut-off that 
maximized sensitivity and specificity for distinguishing between TB groups were generated 
for each of the antibody responses. This was done following the approach by Lopez-Raton et 
al18 implemented in the R package optimal.cutpoints. Pearson correlations plot of the 
antibody responses that had AUC >0.5 was generated. An optimal subset of antibody 
responses, among those that had AUC >0.5 derived from optimal.cutpoints, was selected 
using the cross-validated generalized linear model regularization path algorithm of Friedman 
et al.19 This uses the elastic net penalty for including predictors in the model, and it is 
implemented in the R package cv.glmnet.20 For each individual child, the model was used to 
provide an in-sample prediction of the probability of TB status and the box plots of these are 
presented. Further details of the implementation of cv.glmnet are provided in the online data 
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supplement (Supplemental Digital Content 1, http://links.lww.com/INF/C768). These 
analyses were applied to determine predictive sets of antibody responses that discriminated 
between confirmed TB and unlikely TB groups. The age effect on the predictive power of 
antibody responses was investigated for the confirmed TB versus unlikely TB comparison, 
stratifying by 12–59 and ≥60 months of age. The empiric AUCs were also calculated to 
determine antibody responses that discriminated between the following pairs of TB groups: 
(1) confirmed TB versus unlikely TB/TST-positive; (2) confirmed TB versus unlikely TB/
TST-negative and (3) confirmed TB versus unconfirmed TB. We estimated that a minimum 
of approximately 40 samples in the confirmed TB group was required to detect a significant 
reactivity difference between the confirmed TB group and the unlikely TB group assuming 
60 peptides, a maximum of 0.05 false positives, a desired 0.35 reactivity difference, power 
of 85%, SD of 0.6 and a ratio of 2:1 for number of unlikely TB samples-to-confirmed TB 
samples.
RESULTS
Characteristics of study participants at enrollment are shown in Table 1. Median age was 41 
months [interquartile range (IQR): 24–66 months), and 97 (49%) were male. The most 
prevalent symptoms and signs across groups were cough or other respiratory symptoms 
(69%–90%) and weight loss (63%–70%). There were no significant differences in the 
prevalence or duration of the assessed symptoms or signs among the 3 TB classification 
groups.
Antibody Responses That Discriminate Between Confirmed TB Versus Unlikely TB
The AUCs and the antibody response cut-offs that optimized specificities and sensitivities 
for all antigens considered singly are shown in Table S2 (Supplemental Digital Content 1, 
http://links.lww.com/INF/C768). Forty-two of 119 antigens had AUCs between 0.5 and 0.63. 
The top 10 (of 119) of these antigens are shown in Figure 1A, and the log2-transformed 
antigen responses for those 10 antigens are shown in Figure 2A. The sensitivity was highest 
(60%) for DID64_IDRI, Rv3875_FIND and Rv2873_FIND, and specificity was highest for 
Rv3875_FIND (61%) and DID64_IDRI (60%) (Table S2, Supplemental Digital Content 1, 
http://links.lww.com/INF/C768). The heatmap of the Pearson correlations of the antibody 
responses with AUC >0.5 for the confirmed TB versus unlikely TB comparison (all ages) is 
shown in Figure 3.
For discrimination of confirmed TB versus unlikely TB, stratifying by age [12–59 months of 
age (n = 36) and ≥60 months of age (n = 84)] revealed better antigen prediction power in the 
older age group, with substantially higher AUCs (up to 0.76 for DID64_IDRI) for the older 
age group (Fig. 1C) than for the younger group (Fig. 1B). DID64_IDRI, Rv3875_FIND and 
Rv3616_FIND_A.5 were among the top 10 most predictive antigens common across all the 
stratifications antigens. To illustrate the distribution of these responses, Figure 2B and C 
show the log2-transformed antigen responses for the top 10 antigens for the younger group 
and the older group, respectively, for the comparison of confirmed TB versus unlikely TB. 
There was large variability and overlapping distributions between the 2 TB groups, but older 
children with confirmed TB had higher median values than older children in the unlikely TB 
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group (Fig. 2C). The AUCs, optimal antibody response cut-points, as well as the sensitivities 
and specificities for all antigens considered singly, are shown in Table S3 (Supplemental 
Digital Content 1, http://links.lww.com/INF/C768) (children 60 months old or older) and 
Table S4 (Supplemental Digital Content 1, http://links.lww.com/INF/C768) (children 12–59 
months old).
The antigens selected by the cross-validated generalized elastic.net algorithm are listed in 
Table 2, and the in-sample predictions of risk probabilities from the resultant model are 
shown in Figure 4 for all ages and by age strata. For all ages, 3 antigens were selected and 
the corresponding model assigned a similar median risk probability (0.33) to the confirmed 
TB and the unlikely TB groups. For the younger age group, all the antigens were considered 
by the algorithm to be noise and none of the antigens was selected, hence the resultant TB 
risk probability was equal to an average across both TB groups (0.27). For the older age 
group, the algorithm selected 24 antigens and the resultant model assigned a TB risk 
probability of 0.57 (IQR: 0.48–0.64) to the confirmed TB group versus 0.35 (IQR: 0.32–
0.40) to the unlikely TB group.
Antibody Responses That Discriminate Between Confirmed TB Versus Unlikely TB, by TST 
Status
The empiric AUC values and optimal cut-points for comparing the confirmed TB group (n = 
40) to the group classified as unlikely TB/TST-negative (n = 41) are reported in Table S5 
(Supplemental Digital Content 1, http://links.lww.com/INF/C768). All but 12 of the 119 
antigens had AUC ≥0.5; Rv3875_FIND had the highest AUC (0.74), and sensitivity and 
specificity of 0.70 and 0.71, respectively. The empiric AUC values and optimal cut-points 
for comparing the confirmed TB group (n = 40) to the group classified as unlikely TB/TST-
positive (n = 39) are reported in Table S6 (Supplemental Digital Content 1, http://
links.lww.com/INF/C768). Only 9 of the 119 antigens had AUCs above 0.5; DID64_IDRI 
had the highest AUC (0.59), and sensitivity and specificity of 0.60 and 0.64, respectively.
Antibody Responses That Discriminate Between Confirmed TB Versus Unconfirmed TB
The empiric AUC values and optimal cut-points for comparing the confirmed TB group (n = 
40) to the unconfirmed TB group (n = 39) are reported in Table S7 (Supplemental Digital 
Content 1, http://links.lww.com/INF/C768); Rv1886_FIND had the highest AUC (0.63), and 
sensitivity and specificity of 0.60 and 0.62, respectively.
DISCUSSION
To our knowledge, this is the first study assessing a well-defined multiplex panel of antigens 
for serodiagnosis of childhood TB. In this study of HIV-uninfected children, we found that 
those with active TB had serologic responses against a broad set of M. tuberculosis antigens. 
However, for the main comparison—children with confirmed TB versus children with 
unlikely TB—no single antigen or combination of antigens had sensitivity and specificity 
above about 60%. Findings were similar for the secondary but clinically important 
comparison of children with confirmed TB versus children with unconfirmed TB. To put our 
results into context, the World Health Organization target product profile for a TB detection 
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test has a minimal requirement of specificity ≥98% and sensitivity ≥65%. The target product 
profile for a TB triage test (i.e., a sensitive but not necessarily highly specific rapid “rule-
out” test intended to identify individuals who require additional TB testing) has minimum 
specificity and sensitivity requirements of ≥70% and ≥90%, respectively. Our results did not 
identify a single antigen or combination of antigens fulfilling these requirements and thereby 
holding promise for use as a detection or triage test suitable for application to children of all 
ages with TB signs/symptoms.
We found, however, that the capability of antibody responses to distinguish between TB 
groups was affected by age. Variation in antibody responses by age is initially due to 
maternal antibodies and subsequent maturation of B-cell responses during childhood; in TB, 
there also may be variations in antibody responses because of age-related differences in TB 
disease manifestations.9 We therefore stratified our main analysis by age, specifically 12–59 
and 60+ months old, in line with the age categories used for notification of childhood TB. 
The best-performing single antigens achieved higher discriminatory power in older children 
than in younger children, and the generalized linear model selected a set of antigens that 
warrants further exploration in the older group. Thus, antibody responses may be of some 
use for TB diagnosis in older children, but it may be difficult to identify antigens that will 
deliver the same predictive power for all age groups or for younger children. Better TB 
diagnostic tests are of particular importance in young children in whom the confirmation of 
TB using conventional mycobacterial detection tests is especially challenging. The inability 
to demonstrate a discriminating pattern of antibody response in young children in this study 
is therefore disappointing.
Given that in TB endemic countries, where novel diagnostics are most urgently needed, a 
large proportion of individuals are sensitized to mycobacteria though repeated exposure, it is 
important to ascertain whether prior sensitization with M. tuberculosis interferes with test 
performance. We therefore stratified the main comparison by TST results and found that 
antibody responses were more discriminatory for the confirmed TB versus unlikely TB/TST-
negative comparison than for the confirmed TB versus unlikely TB/TST-positive 
comparison. This may indicate that both humoral and cell-mediated immunity are affected 
by sensitization to mycobacteria, even in the absence of overt disease.
We were not able to identify antibody responses capable of distinguishing children with 
microbiologically confirmed TB from culture-negative children who were clinically 
diagnosed with TB (unconfirmed TB). This is a challenging area for pediatric TB diagnosis, 
since confirming TB among children who are clinically diagnosed, but for whom 
microbiologic investigations are negative, is currently impossible, and over-diagnosis with 
subsequent over-treatment frequently occurs.21 However, we cannot formally exclude the 
possibility that, in our study, children classified as unconfirmed TB truly had TB, a situation 
that could account for the overall similarity in antibody responses between these groups. 
Previous studies in adults have shown that antibody responses to M. tuberculosis antigens 
are highly heterogeneous among individuals.10,11 The current study has also found such 
heterogeneity, some of which was explained by the age of the children.
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From a methodologic perspective, the first stage of our analytical process involved 
generating AUC from the empiric receiver–operator characteristics of the raw data and 
determining the optimal cut-offs for maximizing sensitivity and specificity. The second stage 
was aimed at finding combinations of antibody responses that improved predictive power. 
Because of the high correlations of some of the antibody responses, the cross-validated 
generalized elastic net regularization path algorithm (cv.glmnet) with a logit link was found 
to be superior to other available approaches for finding optimal combinations of correlated 
predictors. cv.glmnet was applied to a subset of those antibody responses that were at least 
weakly informative (AUC: >0.5), to reduce noise from noninformative antigens. The AUCs 
for each antigen were determined empirically and independently of other antibody 
responses, whereas the multivariable regression model fitted via cv.glmnet was a model-
based optimization of the logit coefficients in the presence of confounding responses to other 
antigens. Thus, the 2 analytical approaches provide complementary information in the 
context of this exploratory study.22 The predicted link function from the cv.glmnet model is 
the optimal linear combination of selected antibody responses. This approach to estimation 
of risk probabilities to distinguish between TB groups is similar to the approach followed by 
Anderson et al23 who generated risk scores for HIV status using individual HIV RNA 
signature data in South African and Malawian children. In the current study, however, no 
validation samples were available on which to test the resultant model, and thus only the in-
sample risk probabilities have been presented.
There are several additional limitations to our study. We studied only protein antigens, 
largely based on their identification in recent immunoproteome work,13 and we did not 
assess for antibody responses to other biochemical classes of antigens such as 
lipopolysaccharides. Serologic testing was restricted to IgG antibodies in our study. IgA and 
IgM responses to a number of M. tuberculosis antigens have been demonstrated in serum 
from TB patients and individuals with latent M. tuberculosis infection,8,24,25 and recent 
findings suggest that different antibody isotypes may differentially affect infection of cells 
by M. tuberculosis.26 Further, our experimental methods did not assess antibody 
glycosylation, the extent of which has been associated with activity in vitro.27 Finally, we 
cannot exclude the possibility of classification biases within the consensus case definitions. 
This is relevant to age as a confounder, since age is associated with diagnostic classification 
of children with suspect TB,28 and in our study, it is associated with serologic responses.
Positive antibody reactivity signals may have been confounded by cross-reactivity with 
Mycobacterium bovis BCG and/or non-TB mycobacteria. In South Africa, BCG vaccination 
is recommended at birth and coverage is estimated to be at least 90%.29 Comparative 
genomic studies have identified a number of genomic regions [regions of difference (RD)] 
that are present in M. tuberculosis complex but absent from M. bovis BCG and most non-TB 
mycobacteria.30–32 Our antigen set contained RD1 proteins (Rv3872, Rv3874, Rv3875, 
Rv3878, Rv3879c), RD2 proteins (Rv1980, Rv1980c, Rv1984), an RD3 protein (Rv1586c) 
and an RD4 protein (Rv0222). Interestingly, for discrimination of confirmed TB versus 
unlikely TB, the RD1 antigens Rv3874 and Rv3875 were among the most predictive when 
antigens were considered singly and also comprised the best-performing antigen 
combination as selected by the cross-validated generalized elastic net regularization path 
algorithm.
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FIGURE 1. 
Plots of empiric AUCs for the 10 single antigens having the highest AUC for discrimination 
between children classified as confirmed TB versus children classified as unlikely TB for 
(A) all ages; (B) children 12–59 months old and (C) children 60 months old and older.
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FIGURE 2. 
Boxplots of the log2-transformed antibody responses for the 10 single antigens having the 
highest AUC for discrimination between children classified as unlikely TB (designated as 0 
on the x axis) versus children classified as confirmed TB (designated as 1 on the x axis) for 
(A) all ages; (B) children 12–59 months old and (C) children 60 months old and older. The y 
axis represents log2-transformed antibody responses.
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FIGURE 3. 
Correlations plot of single antibody responses with AUC >0.5 for discrimination between all 
children classified as confirmed TB versus all children classified as unlikely TB.
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FIGURE 4. 
Boxplots of risk probabilities and corresponding receiver–operator characteristic curves for 
optimal antigen combinations selected by the cross-validated generalized linear model 
regularization path algorithm for discrimination between children classified as confirmed TB 
versus children classified as unlikely TB for (A) all ages; (B) children 12–59 months old and 
(C) children 60 months old and older.
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TABLE 2
Antigen Listings for the Optimal Antigen Combinations Selected by the Cross-validated Generalized Linear 
Model Regularization Path Algorithm for Discrimination Between Children Classified as Confirmed TB 
Versus Children Classified as Unlikely TB for All Ages, Children 12–59 Months Old and Children 60 Months 
Old and Older
All Ages
Age
12–9 Months Age ≥60 Months
Rv3874_IDRI None Rv0456c_FIND_A.1
C10.E6_IDRI Rv0934_FIND_A.1
Rv3874.Rv3875_SSI Rv3616_FIND_A.5
Rv3628_FIND_A.4
Rv0934_IDRI
Rv2873_IDRI
C10.E6_IDRI
DID64_IDRI
Rv1099_IDRI
Rv1886_IDRI
Rv2032_IDRI
Rv2220_IDRI
TBF10_IDRI
Rv1636_SSI
Rv3872_SSI
Rv3874.Rv3875_SSI
Rv3874_Lionex
Rv3875_Lionex
Rv1886_FIND
Rv2396_FIND
Rv2873_FIND
Rv3810_FIND
Rv2875_FIND
Rv3875_FIND
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